Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Experimental RNAi

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...

siRNA - Small Interfering RNAs

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...

RNA Interference

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...

RNA Interference

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...

Types of RNA

Types of RNA

Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in regulating gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA Performs Diverse...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Moving toward a gene therapy for Huntington's disease.

Gene therapy·2015

Same author

Hot Topics in Research: Preventive Neuroradiology in Brain Aging and Cognitive Decline.

AJNR. American journal of neuroradiology·2015

Same author

Caspases in Huntington's disease.

The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry·2002

Same author

Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease.

Science (New York, N.Y.)·2001

Same author

Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction.

Neurosurgery·2001

Same author

Prevention of nuclear localization of activated caspases correlates with inhibition of apoptosis.

Apoptosis : an international journal on programmed cell death·2001

Search research articles

Related Experiment Video

Updated: May 26, 2026

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Published on: September 5, 2016

Using non-coding small RNAs to develop therapies for Huntington's disease.

Y Zhang¹, R M Friedlander

¹Department of Neurological Surgery, UPMC Presbyterian Hospital, University of Pittsburgh Medical Center, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.

|December 14, 2011

Summary

This summary is machine-generated.

Small RNA interference offers a promising therapeutic strategy for Huntington's disease (HD). By silencing the mutant HD gene, this approach shows potential to inhibit neurodegeneration and improve motor function in HD patients.

More Related Videos

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders

Published on: April 3, 2021

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Published on: August 10, 2018

Related Experiment Videos

Last Updated: May 26, 2026

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Published on: September 5, 2016

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders

Published on: April 3, 2021

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Published on: August 10, 2018

Area of Science:

Neuroscience
Genetics
Molecular Biology

Background:

Huntington's disease (HD) is an incurable autosomal-dominant neurodegenerative disorder.
It is caused by a CAG triplet expansion in the HD gene, leading to an elongated polyglutamine tract in huntingtin protein.
Current treatments manage symptoms but do not address the underlying genetic cause.

Purpose of the Study:

To explore the therapeutic potential of small non-coding RNA interference for Huntington's disease.
To evaluate the efficacy of silencing the mutant HD allele as a treatment strategy.
To assess the impact of gene silencing on neurodegeneration and disease progression.

Main Methods:

Application of small RNA interference (RNAi) in pre-clinical HD models (animal models and patient-derived cells).
Both allele-non-specific and allele-specific silencing of the mutant HD gene were investigated.
Evaluation of neurodegeneration, motor control, and survival rates in treated HD models.

Main Results:

Silencing the mutant HD transgene significantly inhibited neurodegeneration in HD mouse models.
Improved motor control and extended survival were observed in mice treated with small RNA interference.
The study demonstrated the feasibility of targeting the disease's genetic root cause.

Conclusions:

Small non-coding RNA interference represents a promising therapeutic avenue for Huntington's disease.
Further optimization of allele selectivity, specificity, efficacy, safety, and delivery methods is crucial for clinical translation.
Post-transcriptional gene silencing offers a targeted approach to combat HD's underlying etiology.